• PDF: Delivered by email usually within 48 UK business hours.

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

  • Publication Date:July 2013
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:82
  • ISBN:1853455

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Arimenda is a once-daily fixed-dose combination (FDC) of an ER form of memantine, an NMDA receptor antagonist, and donepezil, an AChEI. It is developed to overcome low compliance in patients who are taking the two drugs separately. It provides full-strength dosing from the start of treatment to enable a more rapid and convenient attainment of therapeutic plasma levels of the two compounds.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Arimenda including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Arimenda for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Arimenda performance
- Obtain sales forecast for Arimenda from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer's Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Strategic Competitor Assessment 40
6 Opportunity and Unmet Need 43
6.1 Unmet Needs Overview 43
6.1.1 Public Awareness 45
6.1.2 Specialized Institutions at Local Levels 46
6.1.3 Screening and Diagnosis 46
6.1.4 Early Intervention 47
6.1.5 Improved Clinical Trial Design 48
6.1.6 Effective Therapy 49
6.1.7 Behavioral Treatments 50
6.2 Gap Analysis 50
6.2.1 Disease Prevention 51
6.2.2 Diagnosis from Biomarkers 52
6.2.3 Behavioral Therapies 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Early-Stage Pipeline Assessment 54
7.3 AD Pipeline by Mechanism of Action 56
7.4 Enzymatic Processing 57
7.5 Immunization 58
7.6 Anti-Aggregation 58
7.7 “Me-Too” 59
7.8 Novel Therapeutic Approaches 60
7.9 Technology Trends Analytic Framework 60
7.10 Promising Drugs in Clinical Development 61
8 Arimenda 63
8.1 Overview 63
8.2 Efficacy 63
8.3 Safety 64
8.4 Dosing and Formulation 64
8.5 Potential Clinical Positioning 64
8.6 Potential Commercial Positioning 65
8.7 Pricing and Reimbursement 65
8.8 SWOT Analysis 65
8.9 Forecast 66
9 Appendix 67
9.1 Bibliography 67
9.2 Abbreviations 72
9.3 Methodology 75
9.4 Forecasting Methodology 75
9.4.1 Diagnosed AD patients 75
9.4.2 Percent Drug-treated Patients 75
9.4.3 General Pricing Assumptions 76
9.4.4 Generic Erosion 77
9.4.5 Pricing of Pipeline Agents 77
9.4.6 Alternate Scenarios 77
9.5 Physicians and Specialists Included in this Study 78
9.6 About the Authors 79
9.6.1 Author 79
9.6.2 Global Head of Healthcare 80
9.7 About GlobalData 81
9.8 Disclaimer 81



List of Tables

Table 1:Symptoms of AD 30
Table 2:Guidelines for the Treatment of AD 37
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 38
Table 4:Leading Branded Treatments for AD, 2013 41
Table 5:Overall Unmet Needs - Current Level of Attainment 44
Table 6:Clinical Unmet Needs - Gap Analysis, 2013 51
Table 7:Technology Trends Analytic Framework for the AD Pipeline, 2012 61
Table 8:Comparison of Therapeutic Classes in Development for AD, 2013 61
Table 9:Comparison of Therapeutic Classes in Development for AD, 2013 62
Table 10:Product Profile - Arimenda 63
Table 11:Arimenda SWOT Analysis, 2013 65
Table 12:Global Sales Forecasts ($m) for Arimenda, 2012-2022 66



List of Figures

Figure 1:Atrophy of the Brain in AD 19
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 21
Figure 3:Non-Amyloidogenic Metabolism of APP 23
Figure 4:Amyloidogenic Metabolism of APP 24
Figure 5:Neurofibrillary Tangles 26
Figure 6:Oxidative Damage Due to Free Radicals 28
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 42
Figure 8:AD - Pipeline Drugs by Target, 2012 55
Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 62
+44 20 8816 8548

Ask a question about Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Enter the characters you see in the picture below
Captcha